Amador Bioscience Establishes Clinical Division in Hangzhou

On March 10, 2022, Amador Bioscience announced the establishment of a new clinical business unit in Hangzhou. Patrick Hu, MD, was appointed as the Chief Executive Officer, Clinical Research reporting directly to  Dr. Bing Wang. Dr. Hu will lead the clinical division to establish a complete global service system, and provide integrated clinical research services for innovative pharmaceutical companies.

Amador Bioscience is focusing on clinical pharmacology to drive the development of new drugs, providing full-chain services in clinical development that meet international standards. 

Presently, it has established operating facilities in the United States, Europe, and China. Its customer base ranges from start-up biotechnology companies to multinational pharmaceutical companies. Up to now, the Amador team has successfully completed more than 200 market entry declarations (e.g. NDAs, BLAs, MAAs) for domestic and foreign customers in the United States and Europe. 

Amador’s clinical research business will use its clinical pharmacology features and core advantages to make medical strategies more scientific, improve data quality, improve clinical development efficiency and increase the success rate of listing.

Globalization, science, and cutting-edge are the three keywords for the delivery of Amador’s clinical research solutions.

Dr. Bing Wang, Chairman and Chief Executive Officer of Amador Bioscience introduced that globalization means that the delivered reports and application materials meet the requirements of the global drug regulatory authorities. 

The implementation of clinical research projects relies on Amador’s global team of experts by using science as the main motivator.

Clinical pharmacology guides the development of innovative drugs; medical strategies are more scientific, patient selection is more accurate, and the efficiency of clinical development can be improved dramatically.

By cutting-edge a reference is made to the fact that Amador’s team has supported many first-in-class listings in the world, and their grasp of cutting-edge science can help more innovative drugs to succeed.

Introducing top international talents to build a global team

Dr. Bing Wang: “We warmly welcome the addition of Dr. Zhiqiang Hu, who has extensive expertise and outstanding leadership in the field of global medicine and pharmacovigilance. As a global leader in the successful research and development of innovative drugs, we are looking forward to working with Dr. Hu to help more innovative pharmaceutical companies enter the global market.”

Zhiqiang Hu, MD: “Amador Bioscience aims to use world-class experience and technology to build a bridge for innovative pharmaceutical companies to enter the global market. I am honored to be a part of it. As a practicing doctor, I hope that in the future, I can use my international experience in medicine and pharmacovigilance to lead the clinical division to help more innovative drugs go to the world and benefit patients around the world.”